9 7 6 4 1
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
在部分南方汉族人中 CD31/PECAM-1 基因 Asn563Ser 多态性与动脉粥样硬化性脑梗死相关
Authors Song YM, Li QF, Long LL, Zhang N, Liu YH
Published Date December 2014 Volume 2015:11 Pages 15—20
DOI http://dx.doi.org/10.2147/NDT.S75065
Received 28 September 2014, Accepted 11 November 2014, Published 18 December 2014
Background: CD31, also called platelet endothelial cell adhesion molecule-1
(PECAM-1), is thought to play a role in the pathological mechanisms of
atherosclerosis. Leu125Val polymorphism and elevated plasma levels of soluble
PECAM-1 (sPECAM-1) were found to be associated with cerebral infarction. Our
aim was to investigate the association between the Asn563Ser polymorphism of CD31/PECAM-1 , plasma level of
sPECAM-1, and the risk of atherosclerotic cerebral infarction (ACI) in the
southern Han population of the People’s Republic of China.
Subjects and methods: A total of 147 subjects with ACI and 114 controls were enrolled in the study. The Asn563Ser CD31/PECAM-1 polymorphism was detected using the polymerase chain reaction–restriction fragment length polymorphism method. The plasma spECAM-1 level was measured using the enzyme-linked immunosorbent assay method.
Results: In this study, statistically significant differences in Asn563Ser genotype and allele distribution were found between the cases and controls (P <0.05). Furthermore, logistic regression analysis showed that the GG genotype is associated with increase in ACI risk (odds ratio =4.862, P <0.001). The plasma level of sPECAM-1 was associated with ACI (odds ratio =1.431, P =0.038). In both the ACI and the control groups, the plasma sPECAM-1 level in subjects with the GG genotype was higher than that in subjects carrying the AA or GA genotype (P <0.05).
Conclusion: Our study showed that the Asn563Ser polymorphism of CD31/PECAM-1 gene and elevated plasma sPECAM-1 level are related to ACI risk in the southern Han population of People’s Republic of China.
Keywords: genetic polymorphism, CD31, platelet endothelial cell adhesion molecule-1 (PECAM-1)
Subjects and methods: A total of 147 subjects with ACI and 114 controls were enrolled in the study. The Asn563Ser CD31/PECAM-1 polymorphism was detected using the polymerase chain reaction–restriction fragment length polymorphism method. The plasma spECAM-1 level was measured using the enzyme-linked immunosorbent assay method.
Results: In this study, statistically significant differences in Asn563Ser genotype and allele distribution were found between the cases and controls (P <0.05). Furthermore, logistic regression analysis showed that the GG genotype is associated with increase in ACI risk (odds ratio =4.862, P <0.001). The plasma level of sPECAM-1 was associated with ACI (odds ratio =1.431, P =0.038). In both the ACI and the control groups, the plasma sPECAM-1 level in subjects with the GG genotype was higher than that in subjects carrying the AA or GA genotype (P <0.05).
Conclusion: Our study showed that the Asn563Ser polymorphism of CD31/PECAM-1 gene and elevated plasma sPECAM-1 level are related to ACI risk in the southern Han population of People’s Republic of China.
Keywords: genetic polymorphism, CD31, platelet endothelial cell adhesion molecule-1 (PECAM-1)
